---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014270"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:35:35.735637+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q2 revenue down 6% YoY, core revenue down 14%; expects 2023 core revenue flat to 2022

## Summary
- Total revenue $9.0M in Q2 2023 (-6% YoY); core business revenue $8.3M (-14% YoY).
- Net loss $10.5M in Q2 vs $8.3M loss in Q2 2022; EBITDA loss $12.0M vs $8.2M.
- FY2023 guidance: core revenue now expected comparable to 2022 (flat); SPL program revenue unchanged ~$6M.
- Five SPL partnerships signed YTD including Lyell, ViTToria, Prime Medicine; total SPLs at 23.
- Cash and investments $216.1M as of June 30, 2023.

## SEC filing metadata
- accession: 0001558370-23-014270
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/0001558370-23-014270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/mxct-20230809x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014270
- JSON: https://secwatch.observer/filing/0001558370-23-014270.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014270.txt

## Key facts
- Earnings Releases
  MAXCYTE, INC. reported the quarter ended June 30, 2023 results: revenue $9.0 million, net income $10.5 million. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Revenue: $9.0 million
  - Net income: $10.5 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue for the second quarter of 2023 was $9.0 million, compared to $9.6 million in the second quarter of 2022, representing a decline of 6%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/0001558370-23-014270-index.htm
- Earnings Releases
  MAXCYTE, INC. reported the six months ended June 30, 2023 results: revenue $17.6 million, net income $21.4 million. Guidance reaffirmed.
  - Period: the six months ended June 30, 2023
  - Revenue: $17.6 million
  - Net income: $21.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue for the first half of 2023 was $17.6 million, compared to $21.2 million in the first half of 2022, representing a decline of 17%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000155837023014270/0001558370-23-014270-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.